Home  >  Science  >  Publications

Novel Therapies

Nipocalimab (M281), Anti-FcRn Antibody

M254, Hyper-sialylated lgG (hslgG)

  • Hyper-sialylated IgG M254, an Innovative Therapeutic Candidate, Evaluated in Healthy Volunteers and Patients With Immune Thrombocytopenia Purpura: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics --- Santiago Arroyo, MD, PhD; Renger G. Tiessen, MD, PhD; William S. Denney, PhD; Jim Jin, MS; Mattheus Paulus (Thijs) van Iersel, MD; Heidi Zeitz, MEd, CCRA; Anthony M. Manning, PhD; Martin R. Schipperus, MD, PhD; James B. Bussel, MD; American Society of Hematology Annual Meeting, December 7, 2019.View Poster
  • Anti-inflammatory Activity of IgG-Fc; C. Beneduce, E. Kurtagic, C.J. Bosques; Current Topics in Microbiology and Immunology (2019) 423: 35-62; View PDF
  • Washburn N, Schwab I, Ortiz D, Bhatnagar N, Lansing J, Medeiros A, Tyler S, Mekala D, Cochran E, Sarvaiya H, Garofalo K, Meccariello R, Meador J, Rutitzky L, Schultes B, Ling L, Avery W, Nimmerjahn F, Manning A, Kaundinya G and Bosques C. Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity.PNAS 2015 112 (11) E1297-E1306; published ahead of print March 2, 2015, doi:10.1073/pnas.1422481112
  • PEGS - Boston, 2014. Embracing EmComplexity: Understanding IVIgto Rationally Design Novel TherapeuticsView PPT

M230 (CSL730), Recombinant Fc Multimer